Medtronic, Inc. (MDT) PT Raised to $94 at Barclays

Barclays raised its price target on Medtronic, Inc. (NYSE: MDT) to $94.00 (from $90.00) while maintaining a Overweight rating.

Analyst Matt Taylor remains positive on the equity citing anticipation for improving product cycles and Diabetes recovery which could boost revenue growth in H2 2018 and FY 2019 which in turn could expand the multiple from its current discounted level.

You May Also Be Interested In

• JPMorgan Starts Kanzhun Ltd (2076:HK) at Overweight
• JPMorgan Upgrades Nanya Technology Corp (2408:TT) to Overweight
• HSBC Downgrades Stellantis NV (STLA:IM) (STLA) to Reduce